BACKGROUND: Although most observational studies identify viral or bacterial pathogens in 50% or less of patients hospitalized with community-acquired pneumonia (CAP), we previously demonstrated that a multi-test bundle (MTB) detected a potential pathogen in 73% of patients. This study compares detection rates for potential pathogens with the MTB versus the Biofire® Pneumonia FilmArray® panel (BPFA) multiplex PCR platform and presents an approach for integrating BPFA results as a foundation for subsequent antibiotic stewardship (AS) activities. METHODS: Between January 2017 to March 2018, all patients admitted for CAP were enrolled. Patients were considered evaluable if all elements of the MTB and the BPFA were completed, and they met other a priori inclusion criteria. The primary endpoint was the percentage of potential pathogens detected using the MTB (8 viral and 6 bacterial targets) versus the BPFA (8 viral and 18 bacterial targets). Blood and sputum cultures were performed on all patients. Two or more procalcitonin (PCT) levels assisted clinical assessments as to whether detected bacteria were invading or colonizing. RESULTS: Of 585 enrolled patients, 274 were evaluable. A potential viral pathogen was detected in 40.5% with MTB versus 60.9% of patients with BPFA with an odds ratio (95% CI) of 9.00 (4.12 to 23.30) p<0.01. A potential bacterial pathogen was identified in 66.4% with the MTB vs 75.5% with the BPFA odds ratio (95% CI) of 2.09 (1.24 to 3.59), p 0.003). Low PCT levels helped identify detected bacteria as colonizers.
BACKGROUND: Although most observational studies identify viral or bacterial pathogens in 50% or less of patients hospitalized with community-acquired pneumonia (CAP), we previously demonstrated that a multi-test bundle (MTB) detected a potential pathogen in 73% of patients. This study compares detection rates for potential pathogens with the MTB versus the Biofire® Pneumonia FilmArray® panel (BPFA) multiplex PCR platform and presents an approach for integrating BPFA results as a foundation for subsequent antibiotic stewardship (AS) activities. METHODS: Between January 2017 to March 2018, all patients admitted for CAP were enrolled. Patients were considered evaluable if all elements of the MTB and the BPFA were completed, and they met other a priori inclusion criteria. The primary endpoint was the percentage of potential pathogens detected using the MTB (8 viral and 6 bacterial targets) versus the BPFA (8 viral and 18 bacterial targets). Blood and sputum cultures were performed on all patients. Two or more procalcitonin (PCT) levels assisted clinical assessments as to whether detected bacteria were invading or colonizing. RESULTS: Of 585 enrolled patients, 274 were evaluable. A potential viral pathogen was detected in 40.5% with MTB versus 60.9% of patients with BPFA with an odds ratio (95% CI) of 9.00 (4.12 to 23.30) p<0.01. A potential bacterial pathogen was identified in 66.4% with the MTB vs 75.5% with the BPFA odds ratio (95% CI) of 2.09 (1.24 to 3.59), p 0.003). Low PCT levels helped identify detected bacteria as colonizers.
Authors: Seema Jain; Wesley H Self; Richard G Wunderink; Sherene Fakhran; Robert Balk; Anna M Bramley; Carrie Reed; Carlos G Grijalva; Evan J Anderson; D Mark Courtney; James D Chappell; Chao Qi; Eric M Hart; Frank Carroll; Christopher Trabue; Helen K Donnelly; Derek J Williams; Yuwei Zhu; Sandra R Arnold; Krow Ampofo; Grant W Waterer; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Jonathan A McCullers; Andrew T Pavia; Kathryn M Edwards; Lyn Finelli Journal: N Engl J Med Date: 2015-07-14 Impact factor: 91.245
Authors: Maria da Gloria S Carvalho; Maria Lucia Tondella; Karen McCaustland; Luciana Weidlich; Lesley McGee; Leonard W Mayer; Arnold Steigerwalt; Melissa Whaley; Richard R Facklam; Barry Fields; George Carlone; Edwin W Ades; Ron Dagan; Jacquelyn S Sampson Journal: J Clin Microbiol Date: 2007-05-30 Impact factor: 5.948
Authors: Wesley H Self; Robert A Balk; Carlos G Grijalva; Derek J Williams; Yuwei Zhu; Evan J Anderson; Grant W Waterer; D Mark Courtney; Anna M Bramley; Christopher Trabue; Sherene Fakhran; Anne J Blaschke; Seema Jain; Kathryn M Edwards; Richard G Wunderink Journal: Clin Infect Dis Date: 2017-07-15 Impact factor: 9.079
Authors: Richard G Wunderink; Arjun Srinivasan; Philip S Barie; Jean Chastre; Charles S Dela Cruz; Ivor S Douglas; Margaret Ecklund; Scott E Evans; Scott R Evans; Anthony T Gerlach; Lauri A Hicks; Michael Howell; Melissa L Hutchinson; Robert C Hyzy; Sandra L Kane-Gill; Erika D Lease; Mark L Metersky; Nancy Munro; Michael S Niederman; Marcos I Restrepo; Curtis N Sessler; Steven Q Simpson; Sandra M Swoboda; Christina Vazquez Guillamet; Grant W Waterer; Curtis H Weiss Journal: Ann Am Thorac Soc Date: 2020-05
Authors: Ji Hun Jeong; Kyung Hee Kim; Sung Hwan Jeong; Jeong Woong Park; Sang Min Lee; Yiel Hea Seo Journal: J Med Virol Date: 2014-05-06 Impact factor: 2.327
Authors: Natalie J Atallah; Hailey M Warren; Matthew B Roberts; Ramy H Elshaboury; Monique R Bidell; Ronak G Gandhi; Meagan Adamsick; Maryam K Ibrahim; Rupali Sood; Savo Bou Zein Eddine; Matthew J Cobler-Lichter; Natalie J Alexander; Kyle D Timmer; Christine J Atallah; Adam L Viens; Vahe S Panossian; Allison K Scherer; Teddie Proctor; Sherrie Smartt; Alyssa R Letourneau; Molly L Paras; Sascha Johannes; Jan Wiemer; Michael K Mansour Journal: PLoS One Date: 2022-01-13 Impact factor: 3.240
Authors: D Markussen; M Ebbesen; S Serigstad; H M S Grewal; Ø Kommedal; L Heggelund; C H van Werkhoven; D Faurholt-Jepsen; T W Clark; C Ritz; E Ulvestad; R Bjørneklett; S T Knoop Journal: Sci Rep Date: 2022-01-10 Impact factor: 4.379